Loading...
•
Dec 31, 2025
AstraZeneca Q4 2025 Earnings Report
AstraZeneca delivered solid revenue growth and strong operating profit in Q4 2025, driven by Oncology and BioPharmaceuticals.
Key Takeaways
In Q4 2025, AstraZeneca reported total revenue of $15.50bn with strong contributions from Oncology and BioPharmaceuticals. Reported operating profit rose sharply year over year, and EPS growth reflected continued commercial momentum across core franchises.
Total revenue reached $15.50bn in Q4 2025.
Reported EPS was $1.50, while Core EPS was $2.12.
Reported operating profit increased to $2.98bn.
Oncology and BioPharmaceuticals were the main growth drivers.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Management expects continued revenue and core EPS growth into FY 2026, supported by pipeline progress and sustained demand across key medicines.
Positive Outlook
- Mid-to-high single-digit revenue growth expected in FY 2026.
- Low double-digit Core EPS growth anticipated.
- Strong Oncology pipeline readouts expected.
- Continued momentum in BioPharmaceuticals.
- Disciplined SG&A and operating leverage.
Challenges Ahead
- FX volatility could impact reported results.
- Lifecycle pressures on mature products.
- Competitive intensity in select markets.
- Pricing pressure in China.
- R&D spend expected at upper end of guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...